值得注意的是，公司近期宣布，拟配售最多合共5117万股新H股，每股H股配售价4.58港元，预计所得款项总净额预计约2.30亿港元。所得款项净额约70%用于公司ADC候选产品的研发、临床试验、注册备案及其他工作流程；约20%用于公司溶瘤病毒候选产品CG0070的临床试验及其他工作流程；及约10%用于补充公司流动资金及作一般企业用途。Lepu Bio-B (02157) is now up more than 8%. As of press release, it has risen 7.83% to HK$4.82, with a turnover of HK$28.239,500.
The Zhitong Finance App learned that Lepu Bio-B (02157) is now up more than 8%. As of press release, it has risen 7.83% to HK$4.82, with a turnover of HK$28.239,500.
According to the news, at the 2024 ASCO annual meeting, Lepu Biotech announced the clinical phase I/II data of EGFR ADC MRG003 combined with PD-1 monoclonal antibody, and achieved positive curative effects in patients with nasopharyngeal cancer treated with PD-1 + chemotherapy and head and neck cancer patients without systemic treatment. Compared with MRG003 alone, it is expected that the efficacy will be further improved. Lepu Biotech previously announced that the results of the company's three clinical studies on innovative drug candidates and combination therapies were announced at the 2024 ASCO annual meeting.
Notably, the company recently announced that it plans to place up to 51.17 million new H shares, with an placement price of HK$4.58 per H share. The total net proceeds are estimated to be around HK$230 million. About 70% of the net proceeds are used for R&D, clinical trials, registration and other work processes of the company's ADC candidate product; about 20% is used for clinical trials and other work processes of the company's oncolytic virus candidate CG0070; and about 10% is used to supplement the company's working capital and general corporate purposes.
